SEATTLE — In this Healio Video Perspective from the ARVO meeting, Allen C. Ho, MD, FASRS, discusses 12-month data on MCO-010 optogenetic therapy for patients with retinitis pigmentosa.
According to Ho, patients who received high- and low-dose MCO-010 (Nanoscope Therapeutics) saw “significant visual acuity improvements” vs. sham. The safety profile was also promising, with no reported cases of severe inflammation, retinal vasculitis, occlusive vasculitis or optic neuropathies.
“This is a mutation agnostic program. That means it seems to be working regardless of whether or